Original Articles

All Items

In general, this kind of publication should be divided into an Abstract, Introduction, Materials and Methods, Results, Discussion, Conclusions and References. [3500 words max, abstract 180 words max, 30 references max, 3/5 tables and/or figures]

  • Ankle brachial index for the diagnosis of asymptomatic lower extremity peripheral arterial disease

    Francesco Cicconi
    https://doi.org/10.4081/btvb.2024.128
    1037
    PDF: 257

  • Artificial intelligence, platelets and aspirin

    Giovanni de Gaetano
    https://doi.org/10.4081/btvb.2024.130
    279
    PDF: 136

  • Cancer complicated by thrombosis and thrombocytopenia: still a therapeutic dilemma

    Yishi Tan, Marc Carrier, Nicola Curry, Michael Desborough, Kathryn Musgrave, Marie Scully, Tzu-Fei Wang, Mari Thomas, Simon J. Stanworth
    https://doi.org/10.4081/btvb.2024.115
    356
    PDF: 119

  • Cancer-associated ischemic stroke: current knowledge and future directions

    Ronda Lun, Deborah M. Siegal
    https://doi.org/10.4081/btvb.2024.117
    1096
    PDF: 287

  • Endothelial cell dysfunction in cancer: a not-so-innocent bystander

    Betül Ünlü, Neha Joshi, Jamie M. O'Sullivan
    https://doi.org/10.4081/btvb.2024.116
    942
    PDF: 146

  • Factor XI inhibitors: a new option for the prevention and treatment of cancer-associated thrombosis

    Marcello Di Nisio, Matteo Candeloro, Nicola Potere, Ettore Porreca, Jeffrey I. Weitz
    https://doi.org/10.4081/btvb.2024.118
    450
    PDF: 192

  • Location of metastasis and complications in patients with venous thromboembolism and cancer: a systematic review

    Maria Barca-Hernando, Victor Garcia-Garcia, Luis Jara-Palomares
    https://doi.org/10.4081/btvb.2024.114
    306
    PDF: 110

  • Machine learning in cancer-associated thrombosis: hype or hope in untangling the clot

    Rushad Patell, Jeffrey I. Zwicker, Rohan Singh, Simon Mantha
    https://doi.org/10.4081/btvb.2024.123
    945
    PDF: 197

  • New drugs, old problems: immune checkpoint inhibitors and cancer-associated thrombosis

    Mehrie H. Patel, Alok A. Khorana
    https://doi.org/10.4081/btvb.2024.113
    294
    PDF: 160

  • Oral Communications and Posters

    Guest Editors: Anna Falanga, Benjamin Brenner, Alok A. Khorana
    https://doi.org/10.4081/btvb.2024.139
    267
    PDF: 278

  • Patient and public involvement in cancer-associated thrombosis research: necessary or glorified tokenism?

    Simon Noble
    https://doi.org/10.4081/btvb.2024.125
    988
    PDF: 116

  • Risk of recurrent venous thromboembolism in cancer patients after discontinuation of anticoagulant therapy

    Gary E. Raskob
    https://doi.org/10.4081/btvb.2024.124
    344
    PDF: 159

  • Trends and updates on the epidemiology of cancer-associated thrombosis: a systematic review

    Ang Li, Emily Zhou
    https://doi.org/10.4081/btvb.2024.108
    460
    PDF: 174

  • Venous thromboembolism and mortality in patients with hematological malignancies

    Kristen M. Sanfilippo, Tzu-Fei Wang
    https://doi.org/10.4081/btvb.2024.119
    318
    PDF: 126

  • Venous thromboembolism treatment in patients with cancer: reflections on an evolving landscape

    Agnes Y.Y. Lee
    https://doi.org/10.4081/btvb.2024.111
    1262
    PDF: 215

  • Welcome to the 12th ICTHIC!

    Guest Editors: Anna Falanga, Benjamin Brenner, Alok A. Khorana
    https://doi.org/10.4081/btvb.2024.138
    1253
    PDF: 168